Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- NANO MRNA to Launch Investment Arm, Set Up Fund with SBI to Acquire Unlisted Biotechs
October 10, 2025
- Japan’s Medical and Pharma DX Market to Reach 1.35 Trillion Yen in 2035: Fuji Keizai
October 10, 2025
- Nichi-Iko to Offload AGs of Allegra and Plavix to Meiji Group
October 8, 2025
- NHI-Market Price Gap Likely to Narrow Further in 2025; Will It Drop into 4% Zone?
October 8, 2025
- Kissei Grants Linzagolix Rights to Searchlight in Canada
October 8, 2025
- Enhertu Combo Filed for First-Line HER2 Breast Cancer in Japan
October 8, 2025
- Leqembi Iqlik Autoinjector Now Available in US: Eisai/Biogen
October 8, 2025
- Japan Ethical Drug Sales Edge Up 0.4% in August: Crecon
October 8, 2025
- Pharma Industry Generally Welcomes New LDP Leader Takaichi
October 7, 2025
- Boehringer Ingelheim Taps Marc Hasson to Lead Japan Operations
October 7, 2025
- Chugai CEO Lauds Sakaguchi’s Nobel-Winning Work
October 7, 2025
- Alfresa, Kidswell, and Others to Form JV for Biosimilar Production in Japan
October 7, 2025
- Gilead Opens Japan Facility to Support CAR-T Delivery
October 7, 2025
- Datroway Hits Key Goals in Global PIII Trial for TNBC: Daiichi Sankyo
October 7, 2025
- SymBio Kicks Off Global PIII Trial of Brincidofovir in Europe
October 7, 2025
- Keytruda Maintains No. 1 Spot for 24th Straight Month: Encise
October 7, 2025
- Takeda Pulls Plug on Cell Therapy Work after Strategy Review
October 6, 2025
- LEO Pharma Begins Promotional Activities for Spevigo in Japan
October 6, 2025
- Sanofi Files ITP Drug Rilzabrutinib in Japan
October 6, 2025
- Moderna Reaffirms Japan Commitment, Denies Downsizing Concerns
October 3, 2025
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…